Table 1.
Baseline characteristics of ADPKD patients (n = 302)
| Characteristics | All patients (n = 302) | Rapid progressors (n = 74) | Slow progressors (n = 78) | p value |
|---|---|---|---|---|
| Gender, female, n (%) | 161 (53.3) | 38 (51.4) | 43 (55.1) | 0.64 |
| Age, years | 48.3±7.43 | 47.8±6.74 | 49.2±7.6 | 0.25 |
| Weight, kg | 84.0±16.9 | 84.9±16.9 | 82.3±17.7 | 0.38 |
| Height, cm | 176±9.89 | 176±10.7 | 175±8.41 | 0.47 |
| BSA, m2 | 1.99±0.22 | 2.00±0.22 | 1.97±0.22 | 0.32 |
| SBP, mm Hg | 133±13 | 135±13 | 132±15 | 0.14 |
| DBP, mm Hg | 82±9 | 82±10 | 82±10 | 0.80 |
| AHT, n (%) | 275 (91.1) | 69 (93.2) | 68 (87.2) | 0.21 |
| RAASi, n (%) | 249 (82.5) | 60 (81.1) | 66 (84.6) | 0.56 |
| eGFR, mL/min/1.73 m2 | 51.6±11.6 | 48.8±11.2 | 54.8±11.3 | 0.001 |
| htTKV, mL/m | 1,082 (736-1,669) | 1,095 (832-1,786) | 952 (652-1,505) | 0.06 |
| PKD mutation, n (%) | ||||
| PKD1 truncating | 139 (46.0) | 41 (55.4) | 30 (38.5) | 0.08 |
| PKD1 nontruncating | 79 (26.1) | 20 (27.1) | 21 (26.9) | |
| PKD2 | 59 (19.6) | 8 (10.8) | 18 (23.0) | |
| No mutation detected | 15 (5.0) | 2 (2.7) | 7 (9.0) | |
| Missing | 10 (3.3) | 3 (4.1) | 2 (2.6) |
Variables are presented as mean ± SD or as median (IQR) in case of nonnormal distribution.
p values for fast versus slow progressors are calculated using independent-sample t test in case of normal distribution, Mann-Whitney U in case of nonnormal distribution, and chi-square in case of categorical data. Rapid and slow progressors were defined as patients with an annual change in eGFR less than or equal to −3.5 or greater than −3.5 mL/min/1.73 m2, respectively.
ADPKD, autosomal dominant polycystic kidney disease; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; AHT, anti-hypertensive therapy; RAASi, RAAS inhibitors; eGFR, estimated glomerular filtration rate; htTKV, height-adjusted total kidney volume; PKD, polycystic kidney disease.